dc.contributor.author | Farrugia, AJ | |
dc.contributor.author | Calvo, F | |
dc.date.accessioned | 2016-10-19T16:15:47Z | |
dc.date.issued | 2017-01-02 | |
dc.identifier.citation | Small GTPases, 2017, 8 (1), pp. 49 - 57 | |
dc.identifier.issn | 2154-1248 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/176 | |
dc.identifier.eissn | 2154-1256 | |
dc.identifier.doi | 10.1080/21541248.2016.1194952 | |
dc.description.abstract | Rho family GTPases such as Cdc42 are key regulators of essential cellular processes through their effects on cytoskeletal dynamics, signaling and gene expression. Rho GTPases modulate these functions by engaging a wide variety of downstream effectors. Among these effectors is the largely understudied Cdc42EP/BORG family of Cdc42 effectors. BORG proteins have been linked to actin and septin regulation, but their role in development and disease is only starting to emerge. Recently, Cdc42EP3/BORG2 was shown to coordinate actin and septin cytoskeleton rearrangements in cancer-associated fibroblasts (CAFs). Interestingly, Cdc42EP3 expression potentiated cellular responses to mechanical stimulation leading to signaling and transcriptional adaptations required for the emergence of a fully activated CAF phenotype. These findings uncover a novel role for the BORG/septin network in cancer. Here, we demonstrate that Cdc42EP3 function in CAFs relies on tight regulation by Cdc42. | |
dc.format | Print-Electronic | |
dc.format.extent | 49 - 57 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Informa UK Limited | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Actins | |
dc.subject | cdc42 GTP-Binding Protein | |
dc.subject | GTP-Binding Protein Regulators | |
dc.subject | Signal Transduction | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Septins | |
dc.subject | Cancer-Associated Fibroblasts | |
dc.title | Cdc42 regulates Cdc42EP3 function in cancer-associated fibroblasts. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-05-23 | |
rioxxterms.versionofrecord | 10.1080/21541248.2016.1194952 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Small GTPases | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Microenvironment | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Microenvironment | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Tumour Microenvironment | |
dc.contributor.icrauthor | Farrugia, Aaron | |